These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 36136330)

  • 1. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
    Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
    JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care.
    De Silva DL; Stafford L; Skandarajah AR; Sinclair M; Devereux L; Hogg K; Kentwell M; Park A; Lal L; Zethoven M; Jayawardana MW; Chan F; Butow PN; James PA; Mann GB; Campbell IG; Lindeman GJ
    Med J Aust; 2023 May; 218(8):368-373. PubMed ID: 37005005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
    Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
    JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
    Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL
    J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
    Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
    JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
    Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O
    JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients.
    Acevedo F; Walbaum B; Camus M; Manzor M; Muñiz S; Medina L; Petric M; Reyes P; Domínguez F; Puschel K; Merino T; Bravo ML; Pinto MP; Ibáñez C; Hughes K; Sánchez C
    Breast Cancer Res Treat; 2023 Jun; 199(2):363-370. PubMed ID: 36988750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
    AlDubayan SH; Conway JR; Camp SY; Witkowski L; Kofman E; Reardon B; Han S; Moore N; Elmarakeby H; Salari K; Choudhry H; Al-Rubaish AM; Al-Sulaiman AA; Al-Ali AK; Taylor-Weiner A; Van Allen EM
    JAMA; 2020 Nov; 324(19):1957-1969. PubMed ID: 33201204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
    Culver JO; Ricker CN; Bonner J; Kidd J; Sturgeon D; Hodan R; Kingham K; Lowstuter K; Chun NM; Lebensohn AP; Rowe-Teeter C; Levonian P; Partynski K; Lara-Otero K; Hong C; Morales Pichardo J; Mills MA; Brown K; Lerman C; Ladabaum U; McDonnell KJ; Ford JM; Gruber SB; Kurian AW; Idos GE
    Cancer; 2021 Apr; 127(8):1275-1285. PubMed ID: 33320347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline Genetic Testing After Cancer Diagnosis.
    Kurian AW; Abrahamse P; Furgal A; Ward KC; Hamilton AS; Hodan R; Tocco R; Liu L; Berek JS; Hoang L; Yussuf A; Susswein L; Esplin ED; Slavin TP; Gomez SL; Hofer TP; Katz SJ
    JAMA; 2023 Jul; 330(1):43-51. PubMed ID: 37276540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Management of
    Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
    South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal Germline-Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision-Making.
    Shelton C; Ruiz A; Shelton L; Montgomery H; Freas K; Ellsworth RE; Poll S; Pineda-Alvarez D; Heald B; Esplin ED; Nielsen SM
    Ann Surg Oncol; 2024 Jan; 31(1):325-334. PubMed ID: 37814187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline whole genome sequencing in adults with multiple primary tumors.
    Wang Y; Ding Q; Prokopec S; Farncombe KM; Bruce J; Casalino S; McCuaig J; Szybowska M; van Engelen K; Lerner-Ellis J; Pugh TJ; Kim RH
    Fam Cancer; 2023 Oct; 22(4):513-520. PubMed ID: 37481477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
    J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    Chang J; Seng S; Yoo J; Equivel P; Lum SS
    Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline pathogenic variants in cancer risk genes among patients with thyroid cancer and suspected predisposition.
    Kamihara J; Zhou J; LaDuca H; Wassner AJ; Dalton E; Garber JE; Black MH
    Cancer Med; 2022 Apr; 11(8):1745-1752. PubMed ID: 35174967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cascade testing for hereditary cancer: comprehensive multigene panels identify unexpected actionable findings in relatives.
    Heald B; Pirzadeh-Miller S; Ellsworth RE; Nielsen SM; Russell EM; Beitsch P; Esplin ED; Nussbaum RL; Pineda-Alvarez DE; Kurian AW; Hampel H
    J Natl Cancer Inst; 2024 Feb; 116(2):334-337. PubMed ID: 37756683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
    Yap TA; Ashok A; Stoll J; Mauer E; Nepomuceno VM; Blackwell KL; Garber JE; Meric-Bernstam F
    JAMA Netw Open; 2022 May; 5(5):e2213070. PubMed ID: 35594047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.